NRx Pharmaceuticals (NASDAQ: NRXP) has announced that its CEO and Chairman, Prof. Jonathan Javitt, MD, MPH, will engage in a fireside chat at the upcoming BTIG Virtual Biotechnology Conference on July 29–30, 2025. The session, set for 8:00 a.m. EDT on July 30, will include Prof. Samuel Wilkinson, MD, from Yale School of Medicine, and BTIG Research Analyst Dr. Thomas Shrader. The discussion will center on the role of neuroplasticity in treating central nervous system (CNS) disorders, with a particular focus on the application of ketamine and other neuroplastic and psychedelic substances for conditions such as depression, suicidality, and PTSD.
NRx Pharmaceuticals is at the forefront of developing therapeutics based on its NMDA platform, targeting CNS disorders including suicidal bipolar depression, chronic pain, and PTSD. The company's flagship investigational product, NRX-101, has been designated as a Breakthrough Therapy by the FDA for suicidal treatment-resistant bipolar depression and chronic pain. NRx is preparing to file a New Drug Application (NDA) for Accelerated Approval of NRX-101, aiming to address the critical needs of patients with bipolar depression and suicidality or akathisia. Furthermore, NRX-101 is being explored as a non-opioid alternative for chronic pain and a potential treatment for complicated urinary tract infections (UTI).
In addition to NRX-101, NRx Pharmaceuticals is advancing NRX-100 (IV ketamine) through the regulatory process for the treatment of suicidal depression. This initiative is supported by data from well-controlled clinical trials conducted under the US National Institutes of Health and recent findings from French health authorities. The FDA has granted Fast Track Designation for the development of ketamine (NRX-100) as part of a protocol aimed at treating acute suicidality, marking a significant milestone in the company's efforts to bring innovative treatments to market.
The participation of NRx Pharmaceuticals in the BTIG Virtual Biotechnology Conference underscores the growing interest and investment in psychedelic and neuroplastic drugs as viable treatments for CNS disorders. This discussion not only highlights the scientific and therapeutic potential of these substances but also reflects the broader shift towards exploring alternative and innovative approaches to mental health and pain management. The implications of this announcement extend beyond the immediate stakeholders, offering hope for patients and families affected by these challenging conditions and signaling a promising direction for the pharmaceutical industry's engagement with psychedelic medicine.
